Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28974097 | 1.00 | TP53 (0.48) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL28010969 | 1.00 | TP53 (0.48) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL4983448 | 0.98 | TP53 (0.52) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL27615745 | 0.95 | — | — | |
| SCHEMBL27326008 | 0.90 | — | — | |
| SCHEMBL27627523 | 0.88 | — | — | |
| SCHEMBL4683222 | 0.80 | CPN1 (0.36) | TP53SLC6A3 | |
| SCHEMBL4683701 | 0.78 | CPN1 (0.42) | TP53KDM4ELMNAMAPTSMN1; SMN2 | |
| SCHEMBL15195460 | 0.74 | TP53 (0.52) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL9580015 | 0.74 | TP53 (0.52) | TP53KDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285699-A | Solid electrolyte prepolymerization liquid, solid electrolyte and electrochemical device | 深圳市贝特瑞新能源技术研究院有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-112852768-B | Carbonyl reductase mutant and application thereof | 中国科学院天津工业生物技术研究所 | 2021-10-08 | — | — | CN | claimed |
| CN-112852768-A | Carbonyl reductase mutant and application thereof | 中国科学院天津工业生物技术研究所 | 2021-05-28 | — | — | CN | claimed |
| CN-117285699-A | Solid electrolyte prepolymerization liquid, solid electrolyte and electrochemical device | 深圳市贝特瑞新能源技术研究院有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-115850115-B | Ruxolitinib intermediate and preparation method thereof | 上海药坦药物研究开发有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-115850115-A | Ruxolitinib intermediate and preparation method thereof | 上海药坦药物研究开发有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2022-04-21 | — | — | US | disclosed |
| CN-112852768-B | Carbonyl reductase mutant and application thereof | 中国科学院天津工业生物技术研究所 | 2021-10-08 | — | — | CN | disclosed |
| CN-112852768-B | Carbonyl reductase mutant and application thereof | 中国科学院天津工业生物技术研究所 | 2021-10-08 | — | — | CN | disclosed |
| CN-112852768-A | Carbonyl reductase mutant and application thereof | 中国科学院天津工业生物技术研究所 | 2021-05-28 | — | — | CN | disclosed |
| CN-112852768-A | Carbonyl reductase mutant and application thereof | 中国科学院天津工业生物技术研究所 | 2021-05-28 | — | — | CN | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
| CN-102026985-A | Quinazoline derivatives as RAF kinase modulators and methods and uses thereof | AMBIT BIOSCIENCES CORPORATON | 2011-04-20 | — | — | CN | disclosed |
| CN-101600707-A | Urea compounds for the treatment of cancer | BAYER PHARMACEUTICALS CORP (US) | 2009-12-09 | — | — | CN | disclosed |
| CN-101553233-A | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-10-07 | — | — | CN | disclosed |
| CN-101553232-A | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-10-07 | — | — | CN | disclosed |
| CN-100448869-C | Anilinopyrazole derivatives for the treatment of diabetes | BAYER PHARMACEUTICALS CORP (US) | 2009-01-07 | — | — | CN | disclosed |
| CN-1946715-A | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORP (US) | 2007-04-11 | — | — | CN | disclosed |
| CN-1717401-A | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORP (US) | 2006-01-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | TP53 725/4885KDM4E 662/4885GMNN 4465/4885 |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | TP53 22/4885KDM4E 2024/4885GMNN 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.